# Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

> **NCT04197713** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 13 (actual)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm
- Unresectable Malignant Solid Neoplasm

## Interventions

- **DRUG:** Adavosertib
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT04197713
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-06-30
- **Primary completion:** 2023-02-22
- **Final completion:** 2026-12-31
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04197713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04197713, "Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04197713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*